This kinase inhibition profile, combined with the paradoxical AMPK activation in cells and arteries, suggests that these new chemical entities may constitute a valuable starting point for the development of new AMPK modulators with therapeutic potential for the treatment of vascular complications associated with obesity. The gene discussed is PRKAB1; the disease is obesity due to melanocortin 4 receptor deficiency.